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Abstract
Background: Immunosuppressed individuals present serious morbidity and mortality from influenza, therefore it is
important to understand the safety and immunogenicity of influenza vaccination among them.
Methods: This multicenter cohort study evaluated the immunogenicity and reactogenicity of an inactivated, monovalent,
non-adjuvanted pandemic (H1N1) 2009 vaccine among the elderly, HIV-infected, rheumatoid arthritis (RA), cancer, kidney
transplant, and juvenile idiopathic arthritis (JIA) patients. Participants were included during routine clinical visits, and
vaccinated according to conventional influenza vaccination schedules. Antibody response was measured by the
hemagglutination-inhibition assay, before and 21 days after vaccination.
Results: 319 patients with cancer, 260 with RA, 256 HIV-infected, 149 elderly individuals, 85 kidney transplant recipients, and
83 with JIA were included. The proportions of seroprotection, seroconversion, and the geometric mean titer ratios
postvaccination were, respectively: 37.6%, 31.8%, and 3.2 among kidney transplant recipients, 61.5%, 53.1%, and 7.5 among
RA patients, 63.1%, 55.7%, and 5.7 among the elderly, 59.0%, 54.7%, and 5.9 among HIV-infected patients, 52.4%, 49.2%, and
5.3 among cancer patients, 85.5%, 78.3%, and 16.5 among JIA patients. The vaccine was well tolerated, with no reported
severe adverse events.
Conclusions: The vaccine was safe among all groups, with an acceptable immunogenicity among the elderly and JIA
patients, however new vaccination strategies should be explored to improve the immune response of immunocompro-
mised adult patients. (ClinicalTrials.gov, NCT01218685)
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Introduction
The novel influenza A (H1N1) virus was first identified in
Mexico in March of 2009 [1], and its rapid global spread made the
World Health Organization (WHO) declare on June 11, 2009 that
a pandemic was under way [2].
According to the WHO, adults and children older than 6
months of age presenting immunosuppressive conditions, and the
elderly should be vaccinated against seasonal influenza, since they
suffer with serious morbidity and mortality from the disease [3].
These recommendations were extended to the pandemic (H1N1)
2009 virus, and the Brazilian Ministry of Health conducted a
nationwide vaccination campaign on March of 2010, vaccinating
more than 80 million individuals [4,5,6].
As this pandemic virus might circulate as the dominant strain
for several years and vaccination will be the most effective
morbidity and mortality preventive measure among the immuno-
suppressed population, to obtain information on the safety and
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27214immunogenicity of this vaccine is crucial to improve vaccination
strategies among them.
Hence, this study was designed to evaluate the immunogenicity
and reactogenicity of an inactivated, split-virus, monovalent, non-
adjuvanted 2009 pandemic influenza A (H1N1) vaccine among
the elderly, HIV-infected, rheumatoid arthritis (RA), cancer,
kidney transplant, and juvenile idiopathic arthritis (JIA) patients.
Methods
Study Design
This multicenter prospective observational cohort study was
conducted from March, 2010 to July, 2010 at Sa ˜o Paulo, Brazil.
Participating clinical sites included the Instituto do Ca ˆncer do
Estado de Sa ˜o Paulo (ICESP), Renal Transplantation Unit,
Division of Rheumatology, Pediatric Rheumatology Unit from
Children’s Institute, all from Faculdade de Medicina da
Universidade de Sa ˜o Paulo, Centro de Refere ˆncia para Imuno-
biolo ´gicos Especiais (CRIE)/Hospital das Clı ´nicas da Universi-
dade de Sa ˜o Paulo, and Centro de Refere ˆncia e Treinamento em
DST/AIDS (CRT-DST/AIDS) of the State of Sa ˜o Paulo. Patients
were invited to participate in the study during their routine clinical
visits at one of the sites.
Ethics Statement
The study was approved by the Ethics Committees of the
Faculdade de Medicina da Universidade de Sa ˜o Paulo, ICESP,
CRT-DST/AIDS of the State of Sa ˜o Paulo, the Brazilian federal
health regulatory agency (ANVISA), and was registered at
ClinicalTrials.gov (NCT01218685). The study was conducted in
accordance with the principles of the Declaration of Helsinki and
Good Clinical Practices [7]. Participants were screened for
eligibility, and enrolled by the Principal Investigators following
the signature of a written informed consent. Those younger than
18 years of age had the written informed consent signed by a
legally acceptable representative.
Study Population
Children 6 months of age and older with JIA [8], kidney
transplant recipients, RA [9], HIV-infected, and cancer patients
18 years of age and older, and elderly 60 years of age and older
without any immunosuppressive condition, hereafter referred to as
the elderly, were eligible to participate in the study (See Appendix
S1 for full eligibility criteria).
Immunogenicity and safety endpoints
The co-primary immunogenicity endpoints were the propor-
tions of seroprotection (postvaccination hemagglutination-inhibi-
tion (HI) antibody titers $1:40), seroconversion (HI antibody titer
prevaccination ,1:10 and postvaccination $1:40 or prevaccina-
tion $1:10 and an increase by a factor of four or more
postvaccination), and the geometric mean ratio of HI antibody
titers.
To be licensed, pandemic influenza vaccines must meet all three
immunologic endpoints established for seasonal influenza vac-
cines: proportions of seroprotection .70% or .60%, of
seroconversion .40% or .30%, and geometric mean ratio of
HI antibody titers .2.5 or 2.0, for adults aged 18–60 years or over
60 years, respectively [10,11]. Similar requirements applied to
adults aged 18–60 years have been proposed to children [12].
Although these endpoints are not applied to immunocompromised
individuals, in this study they were used as parameters to evaluate
the response to the vaccine.
The secondary safety endpoint comprised solicited local (pain,
bruising, redness, and swelling) or systemic (fever, chills, malaise,
myalgia, arthralgia, nausea, and headache) adverse events (AEs)
reported within the first three days postvaccination. Symptoms
were graded as follow: none; mild, if they did not interfere with
normal daily activities; moderate, if they interfered with normal
daily activities; and severe, if participants could not perform daily
activities and/or necessitated medical attention. Fever was defined
as an axillary temperature $37.8uC.
Prior seasonal influenza vaccination was not evaluated, and a
safety monitoring board reviewed reported AEs throughout the
study period.
Study Procedures
The vaccine was administered by intramuscular injection into
the deltoid muscle of the nondominant arm. Children aged 6–35
months received two 0.25 mL doses, and children aged 36 months
to 8 years received two 0.5 mL doses, both approximately 21 days
apart. Children aged 9 years or older, adults, and the elderly
received one 0.5 mL dose. Participants, or their representatives,
were asked to record local and systemic reactions for the next three
days on a diary provided by the investigators.
Vaccine
The inactivated, split-virus, monovalent, non-adjuvanted 2009
pandemic influenza A (H1N1) vaccine was produced by Butantan
Institute/Sanofi Pasteur with seed virus prepared from reassortant
vaccine virus A/California/7/2009 (NYMC X-179A). The
manufacturing process was identical to that applied for the
seasonal vaccine.
The vaccine was supplied as 5 mL multi-dose vials, containing
15 mg of H1 hemagglutinin and 45 mg of thimerosal per 0.5 mL
dose, and was stored at 2–8uC until used.
Laboratory Assays
Blood samples were taken at days 0 and 21 after vaccination or
second vaccination for children younger than 9 years of age.
Antibody response was measured by the hemagglutination-
inhibition assay according to standard methods at the Adolfo Lutz
Institute (Sa ˜o Paulo, Brazil) [13]. Titers were tested at an initial
dilution of 1:10, at a final dilution of 1:2560, and for the purpose of
calculations negative titers had assigned a value of 1:5. Samples
were tested in duplicate, and geometric mean values used in the
analyses.
Statistical Analysis
The proportions of seroprotection, seroconversion, and the
geometric mean ratio of HI antibody titers were obtained for each
group with their respective 95% confidence intervals (CI). A
sensitivity analysis, excluding the participants with prevaccination
HI antibody titers $1:40, was also performed with these
immunologic parameters. Analyses stratified by age (.60 or
#60 years) were performed for kidney transplant recipients, RA,
HIV-infected, and cancer patients. The distribution of HI
antibody titers in each group was described with reverse
cumulative distribution curves.
The geometric mean ratio of HI antibody titers and the
proportion of seroconversion were compared between participants
with prevaccination HI antibody titers ,1:40 and $1:40 in each
group by the two-sided Wilcoxon rank-sum test, and two-sided
Fisher’s exact test, respectively.
Linear and logistic regression were used to evaluated the impact
of prevaccination HI titers $1:40 on the geometric mean ratio of
Pandemic H1N1 (2009) Vaccine and Immunocompromised
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regression models, the geometric mean ratios of HI titers were
natural log transformed, and the coefficients of the prevaccination
HI titers $1:40 variable (coded: 0/no, 1/yes) were exponentiated
to obtain the ratio of the geometric mean ratio of HI titers for
participants with prevaccination HI titer $1:40 and participants
with prevaccination HI titer ,1:40. For linear and logistic
regression, the initial full models were adjusted for age and
gender, and the variables included in the final regression models
were selected by the change-in-estimate procedure with backward
elimination [14]. At each stage, the variable for which removal
caused the smallest change in the prevaccination HI titers $1:40
variable (coded: 0/no, 1/yes) regression coefficient was removed,
given that this change was smaller than 10%. The variances of
regression coefficients were obtained by the Huber-White
sandwich estimator [15,16], and Firth’s penalized likelihood
approach was used to address complete separation [17].
HI antibody titers were natural log transformed for the analyses,
and exact (Clopper-Pearson) CIs were calculated for proportional
endpoints.
The percentages of local and systemic adverse envents were
calculated for each group with their respective 95% confidence
intervals (CI).
All statistical tests used a significance level of 0.05, and all
analyses were performed by one of the authors (J.L.M.) with Stata
10.1 (StataCorp. 2007. Stata Statistical Software: Release 10.
College Station, TX: StataCorp LP).
Results
Study Population
The study enrolled 1152 participants, including 319 patients
with cancer, 260 with RA, 256 HIV-infected, 149 elderly
individuals, 85 kidney transplant recipients, and 83 with JIA.
The baseline characteristics of participants according to study
group are described in Table 1. All groups of immunocompro-
mised individuals, besides JIA, included participants older than 60
years of age. More females were included among the elderly, RA,
and cancer patients, while more males were included among HIV-
infected patients, with no significant difference in the proportion of
males and females included among kidney transplant recipients
and JIA patients. The proportion of prevaccination HI antibody
titers $1:40 ranged from 4.1% among cancer patients to 21.7%
among JIA patients.
Immunogenicity
Table 2 describes the antibody responses after vaccination of the
entire study population, according to immunosuppressive condi-
tion. All study groups achieved a geometric mean ratio of HI
antibody titers .2.5, which ranged from 3.2 among kidney
transplant recipients to 16.5 among JIA patients. Only kidney
transplant recipients did not reach a proportion of seroconversion
.40%, while in the remaining groups it ranged from 49.2%
among cancer patients to 78.3% among JIA patients. The elderly
presented a proportion of seroprotection .60%, and JIA patients
.70%, while in the remaining groups it ranged from 37.6%
among kidney transplant recipients to 59% among the HIV
infected. Figure 1. (A) shows the distribution of HI antibody titers
of the entire study population by study group.
The sensitivity analysis (Table 2. and Figure 1. (B)) showed
similar results to those observed when the entire study population
was analyzed.
The age-stratified analyses only had an impact among kidney
transplant recipients, showing that among this population those
older than 60 years of age did not achieve any of the three
immunologic endpoints evaluated. (Table 1. and Table 2. of the
Appendix S1).
Prevaccination HI Antibody Titers $1:40 and Immune
Response
The unadjusted and adjusted analyses showed that participants
with prevaccination HI antibody titers $1:40 had statistically
significant smaller geometric mean ratios of HI antibody titers,
when compared to participants with prevaccination HI antibody
titers ,1:40, among the elderly, RA, and JIA patients, with a
similar finding among kidney transplant recipients only in the
adjusted analyses (Table 3. and Table 4. of the Appendix S1). The
linear regression models identified a relative reduction of the
geometric mean ratio of HI antibody titers among participants
with prevaccination HI titer $1:40, when compared to partic-
ipants with prevaccination HI titer ,1:40, of 65.8% (95% CI:
47.8–77.6%; P,0.0001) among kidney transplant recipients, of
47.4% (95% CI: 11.3–68.8%; P=0.016) among RA patients, of
47.8% (95% CI: 8.4–70.3%; P=0.024) among the elderly, and of
71.8% (95% CI: 47.5–84.9%; P=0.0001) among IJA patients.
In all study groups, there were no significant differences in
seroconversion among participants with prevaccination HI titers
$1:40 and participants with prevaccination HI titers ,1:40, in
both unadjusted and adjusted analyses (Table 3. and Table 5. of
the Appendix S1).
Safety
Local and systemic AEs are described in Table 3. The most
frequently reported local AE within 3 days after vaccination
among all study groups was pain, which varied from 1.6% among
HIV-infected patients to 33.8% among JIA patients. Among
systemic AEs, headache and chills were reported by all study
groups, while fever was only reported by kidney transplant
recipients and RA patients. Most systemic AEs were reported with
a frequency of less than 10%, with only RA and JIA patients
reporting frequencies greater than 20%. No severe AEs were
reported.
Discussion
Immunosuppressed and elderly individuals present not only
high rates of infection with human seasonal influenza virus, but
also an increased risk to suffer with severe illness [18,19], and
although available, vaccination against seasonal influenza pro-
motes a diminished immune response among them, when
compared to healthy or younger individuals [19,20].
Monovalent, inactivated, non-adjuvanted pandemic 2009
influenza A (H1N1) vaccines have been evaluated in the general
population [21,22,23,24]. Randomized placebo-controlled trials
have demonstrated that these vaccines are safe and widely
immunogenic, with seroprotection rates among healthy adults,
adolescents, and the elderly ranging from 94–98%, 94–97%, and
79–93%, respectively, after a single dose of 15 mg of antigen, and
greater than 98% among healthy children, after two doses of
15 mg of antigen. This prospective study found a similar safety
profile among immunosuppressed and elderly individuals.
Although in this study the elderly presented a seroprotection
rate smaller than previously reported, they showed a satisfactory
immune response to the vaccine achieving the three immunologic
thresholds established for the licensure of pandemic influenza
vaccines (a proportion of seroprotection .60%, of seroconversion
.30%, and a geometric mean ratio of HI antibody titers .2.0). In
the remaining groups, these parameters varied according to the
Pandemic H1N1 (2009) Vaccine and Immunocompromised
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Cancer
Rheumatoid
Arthritis HIV–Infected Elderly
Kidney
Transplant
Juvenile Idiopathic
Arthritis
(N=319) (N=258) (N=255) (N=149) (N=85) (N=83)
Age—yr
Median 62 58 45 68 50 13
Range 17–90 24–83 22–75 60–89 19–69 3–23
Sex
Female
% 64.6 85.7 8.6 69.1 47.1 60.2
(95% CI) (59.1–69.8) (80.8–89.7) (5.5–12.8) (61.0–76.4) (36.1–58.2) (48.9–70.8)
Male
% 35.4 14.3 91.4 30.9 52.9 39.8
(95% CI) (30.2–40.9) (10.3–19.2) (87.2–94.5) (23.6–39.0) (41.8–63.9) (29.2–51.1)
Prevaccination HI titers $1:40
% 4.1 12.3 8.6 12.8 5.9 21.7
(95% CI) (2.2–6.9) (8.6–16.9) (5.5–12.7) (7.9–19.2) (1.9–13.2) (13.4–32.1)
doi:10.1371/journal.pone.0027214.t001
Table 2. Antibody Responses After Vaccination as Measured with the Hemagglutination–Inhibition Assay, According to Group.
Cancer
Rheumatoid
Arthritis HIV Infected Elderly Kidney Transplant
Juvenile Idiopathic
Arthritis
Entire Population (N=319) (N=260) (N=256) (N=149) (N=85) (N=83)
Baseline
Geometric mean titer 6.4 8.3 6.8 9.4 6.8 10.6
(95% CI) (6.0–6.8) (7.4–9.2) (5.8–7.9) (8.1–10.9) (5.8–7.9) (8.1–13.8)
Postvaccination
Geometric mean titer 34 61.8 46.2 53.4 21.3 175.4
(95% CI) (28.9–40.0) (50.2–76.1) (38.1–55.9) (42.9–66.4) (15.1–30.2) (124.6–246.8)
Geometric mean titer ratio 5.3 7.5 5.9 5.7 3.2 16.5
(95% CI) (4.6–6.2) (6.1–9.1) (5.0–6.9) (4.7–6.9) (2.3–4.4) (11.8–23.2)
Seroconversion
a–% 49.2 53.1 54.7 55.7 31.8 78.3
(95% CI) (43.6–54.8) (46.8–59.3) (48.4–60.9) (47.3–63.8) (22.1–42.8) (67.9–86.6)
Seroprotection
b–% 52.4 61.5 59 63.1 37.6 85.5
(95% CI) (46.7–57.9) (55.3–67.5) (52.7–65.1) (54.8–70.8) (27.4–48.8) (76.1–92.3)
Sensitivity Analysis
c (N=306) (N=228) (N=234) (N=130) (N=80) (N=65)
Baseline
Geometric mean titer 5.8 6.2 6.5 7.1 5.8 6
(95% CI) (5.6–6.0) (5.9–6.6) (6.1–6.9) (6.5–7.8) (5.4–6.3) (5.4–6.7)
Postvaccination
Geometric mean titer 31.2 50.7 39.2 44 19.7 133.5
(95% CI) (26.6–36.7) (40.8–63.0) (32.3–47.5) (35.4–54.8) (13.7–28.2) (89.9–198.1)
Geometric mean titer ratio 5.4 8.2 6 6.2 3.4 22.3
(95% CI) (4.6–6.3) (6.6–10.1) (5.1–7.2) (5.0–7.6) (2.4–4.7) (15.1–32.8)
Seroconversion
a–% 48.6 53.9 53.8 56.9 33.8 80
(95% CI) (42.9–54.4) (47.2–60.5) (47.2–60.3) (48.0–65.6) (23.2–44.3) (68.2–88.9)
Seroprotection
b–% 50.3 56.1 55.1 57.7 33.8 81.5
(95% CI) (44.6–56.1) (49.4–62.7) (48.5–61.6) (48.7–66.3) (23.2–44.3) (70.0–90.1)
Anti–hemagglutinin antigen antibody titers below the detection limit (i.e., ,1:10) were assigned a value of 1:5 for purposes of calculations.
aHI titer prevaccination ,1:10 and postvaccination $1:40, or prevaccination $1:10 and an increase by a factor of four or more postvaccination.
bHI antibody titer $1:40.
cThe sensitivity analysis excluded the participants with prevaccination HI antibody titers $1:40.
doi:10.1371/journal.pone.0027214.t002
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may be diminished when compared to those observed in healthy
individuals.
HIV-infected individuals had a diminished immune response to
monovalent, inactivated, non-adjuvanted pandemic (H1N1) 2009
vaccines when compared to healthy controls [25,26]. The
proportions of seroprotection and seroconversion observed among
them ranged from 50–65% and 39–68%, respectively [26,27,28],
responses that are in agreement with our findings. Notably, most
individuals in these previous studies were taking antiretroviral
therapy (82–99%), and presented high median/mean CD4 cell
counts at the moment of vaccination (411–581 cell/ml).
A single study evaluated the same vaccine used in our study in
RA patients and healthy adults [29], and showed an acceptable
and comparable safety profile between them. The proportions of
seroprotection and seroconversion were 60.1% and 53.4%,
considered significantly different from the proportions observed
among healthy individuals, and similar to the proportions of
seroprotection and seroconversion of 61.5% and 53.1%, respec-
tively, observed in our study.
No study, that we are aware of, has evaluated the monovalent,
inactivated, non-adjuvanted pandemic 2009 influenza A (H1N1)
vaccine in adult kidney transplant recipients, cancer, and JIA
patients. Data derived from seasonal influenza vaccination
indicate that antibody responses are diminished among recipients
of solid organ transplants, including kidney transplant, and among
cancer patients [19]. Similar diminished humoral responses were
found to the vaccine evaluated in our study in these populations,
with kidney transplant recipients being the only group that did not
reach acceptable proportions of both seroprotection and serocon-
version, and individuals older than 60 years of age in this group
not reaching acceptable values for any of the three immunologic
endpoints evaluated.
In our study the JIA patients were the only ones that showed a
proportion of seroprotection .70%, of seroconversion .40%,
and a geometric mean ratio of HI antibody titers .2.5, i.e., results
similar to those observed in children with rheumatic diseases who
received seasonal influenza vaccination [30,31,32].
Prevaccination HI antibody titers $1:40 among the study
participants reflected the circulation of the pandemic 2009
influenza A (H1N1) virus in Brazil. The higher proportion among
JIA patients is in accordance with data showing that children 5–14
years of age had the highest rates of infection with this pandemic
virus [33,34].
We speculated that prevaccination HI antibody titers $1:40
could interfere with overall results and individual immunologic
responses, hypotheses that were not confirmed. The sensitivity
analysis did not impact any of the three immunologic endpoints
across all groups. Furthermore, although most individuals with
prevaccination HI antibody titers $1:40 had a smaller increase in
the geometric mean ratio of HI antibody titers, than the ones with
prevaccination HI antibody titers ,1:40, there were no differences
in the proportion of seroconversion between these groups. These
findings, along with existing evidence showing that higher levels of
antibodies could be associated with higher levels of protection from
illness [35], raises the question of whether individuals considered
protected could benefit from vaccination as much as those not
protected. Further studies addressing this issue are warranted,
especially among the population of immunocompromised, since
they present an increased risk to suffer with severe illness related to
influenza, and therefore would benefit from improved immunity.
Finally, the results from our study should be interpreted with
caution, since factors that could have interfered with the immune
response to vaccination, including CD4 cell count, HIV viral load,
use of immunosuppressive drugs like mycophenolate mofetil or
systemic corticosteroids, type of cancer, and timing of vaccination
in relation to chemotherapy were not evaluated [19].
In conclusion, this study demonstrated that the pandemic 2009
influenza A (H1N1) monovalent, inactivated, non-adjuvanted
vaccine has an acceptable safety profile in the elderly and in the
immunocompromised populations herein studied. The immune
response observed among the elderly was similar to that observed
Figure 1. Reverse Cumulative Distribution Curves for Hemagglutination-Inhibition Antibodies Titers on Day 21 After Vaccination.
(A) In the entire study population and (B) Excluding participants with prevaccination HI titers $1:40. The limit of detection was a titer of 1:10. Titers
are expressed as the reciprocal of the dilution.
doi:10.1371/journal.pone.0027214.g001
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responses similar to that observed in health individuals; further
studies addressing different vaccination strategies, as multiple
doses or adjuvanted-vaccines, among kidney transplant recipients,
cancer, HIV-infected, and RA patients are warranted.
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